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ABSTRACT
The current view of cancer progression highlights that cancer cells must undergo 
through a post-translational regulation and metabolic reprogramming to progress 
in an unfriendly environment. In here, the importance of neddylation modification 
in liver cancer was investigated. We found that hepatic neddylation was specifically 
enriched in liver cancer patients with bad prognosis. In addition, the treatment with 
the neddylation inhibitor MLN4924 in Phb1-KO mice, an animal model of hepatocellular 
carcinoma showing elevated neddylation, reverted the malignant phenotype. 
Tumor cell death in vivo translating into liver tumor regression was associated with 
augmented phosphatidylcholine synthesis by the PEMT pathway, known as a liver-
specific tumor suppressor, and restored mitochondrial function and TCA cycle flux. 
Otherwise, in protumoral hepatocytes, neddylation inhibition resulted in metabolic 
reprogramming rendering a decrease in oxidative phosphorylation and concomitant 
tumor cell apoptosis. Moreover, Akt and LKB1, hallmarks of proliferative metabolism, 
were altered in liver cancer being new targets of neddylation. Importantly, we 
show that neddylation-induced metabolic reprogramming and apoptosis were 
dependent on LKB1 and Akt stabilization. Overall, our results implicate neddylation/
signaling/metabolism, partly mediated by LKB1 and Akt, in the development of liver 
cancer, paving the way for novel therapeutic approaches targeting neddylation in 
hepatocellular carcinoma.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
common cancer worldwide and the third leading cause of 
death [1]. HCC etiology is very complex with multiple 
and distinct signaling pathways converging in malignant 
transformation [2]. The current view of cancer progression 
supports that cancer cells must undergo through a post-
translational modification (PTM) regulation and a 
metabolic switch or reprogramming in order to progress 
in an unfriendly environment [3]. Neddylation is a PTM 
by which the ubiquitin-like protein, neural precursor cell 
expressed, developmentally downregulated 8 (Nedd8) 
is conjugated to its target proteins. Since Nedd8 is a 
key regulator of cell growth, viability and malignant 
transformation [4], neddylation inhibition could prove 
to be an effective anti-cancer therapy. Although the 
cullin-RING family of E3 ubiquitin-ligases are the best-
characterized Nedd8 substrates, other proteins have 
been reported to be modified by Nedd8, including p53, 
murine double minute 2 (Mdm2), epidermal growth factor 
receptor, VHL tumour suppressor protein, L11, and other 
RNA binding proteins such as human antigen R (HuR), a 
hallmark of liver tumor progression [5-8]. Although not 
described to date, several other proteins could be potential 
neddylation targets. 
Liver kinase B1 (LKB1) and Akt kinases are 
proteins known to play an important role in metabolism 
regulation [9]. LKB1 directly phosphorylates and 
activates AMP-activated protein kinase (AMPK), a 
central metabolic sensor [10]. Previously, we have shown 
that LKB1 activity, highly representative in HCC patients 
with poor outcome, has a surprising pro-oncogenic role 
in liver tumors through the regulation of one of the major 
oncogenes involved in the development and progression 
of HCC, Ras [11]. Moreover, LKB1 in HCC regulates the 
Akt-survival pathway independently of phosphoinositide 
3-kinase (PI3K) and mammalian target of rapamycin 
(mTOR) [12]. On the other hand, Akt hyperactivation 
can contribute to the genesis of cancer coupled to its role 
in energy metabolism, including the so-called “Warburg 
effect”. The Akt-dependent changes in energy metabolism 
in tumor cells involve a coordinated regulation in both 
glycolysis and oxidative phosphorylation [13]. As with 
LKB1, the deregulation of the PI3K/Akt pathway is 
extremely relevant in HCC with over one hundred Akt 
substrates involved in cell survival, proliferation and 
metabolism [14]. Importantly, LKB1 and Akt are subjected 
to PTM regulatory events, as ubiquitination [15]. To date, 
neddylation regulation of LKB1 and Akt has not been 
described.
Here, we have unraveled that neddylation is 
specifically enriched in HCC patients with poor outcomes 
providing a selective advantage to the tumors. In prohibitin 
1 (Phb1)-KO mice, neddylation inhibition correlates 
with a strong modulation of the cancer metabolic 
signature and liver tumor regression, as a consequence 
of tumor cell death and characterized by: a) reduced 
levels of total sphingomyelines (SM) and a variety of 
diacylglycerols (DAG), succinate, GTP, malonyl-CoA, 
glycine; and b) augmented glycolic acid, triacylglycerols 
(TAG) levels and the phosphatiylcholines (PC) synthesis 
phosphatidylethanolamine methyltransferase (PEMT) 
flux. In protumoral hepatocytes, neddylation inhibition 
resulted in metabolic reprogramming rendering a 
decrease in the oxidative phosphorylation and increased 
glycolysis, associated with cell apoptosis. Importantly, 
we found that LKB1 and Akt are new targets of 
neddylation, undoubtedly providing important insights 
into the regulatory mechanism of these oncokinases and 
reinforcing the role of neddylation as a tumor promoter. 
Evidences of neddylation-mediated driven malignancy 
further implicate this PTM as a potential novel therapeutic 
target during liver tumor management and treatment.
RESULTS
Alteration of neddylation levels is associated with 
liver malignancy in clinical HCC
Dysregulated neddylation pathway was 
previously described in many types of cancer [16]. 
Immunohistochemistry (IHC) analyses revealed 
significantly higher levels of global neddylation and of the 
Nedd8 activating enzyme E1 (NAE1) in malignant tissues 
from a cohort of human HCC (Fig. 1A). Additionally, 
gene expression levels of Nedd8 and NAE1, examined 
by analysis of published microarrays obtained from an 
ONCOMINE search (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE14520), were increased in a cohort 
of 225 HCC human samples versus 200 controls [17] 
(Fig. 1B). Neddylation activity increase is more specific 
of tumoral areas as can be observed in the IHC of a tumor 
with respective surrounding tissue in Suppl. Fig. 1A. 
Importantly, in a prospective study of patients with liver 
cirrhosis on ultrasound surveillance at first diagnosis of 
HCC, global neddylation at protein level as well as Nedd8 
and NAE1 gene expression levels were significantly 
higher in HCC patients with poor prognosis (Fig. 1C-
D). In agreement, Kaplan-Meier plot shows that elevated 
neddylation levels were associated with lower survival 
rates (Fig. 1E), while a logistic regression to quantify the 
predictive value of neddylation revealed an AUC of 0.8 
p<0.014 (Fig. 1F). 
Overall our data underscore a robust regulation of 
neddylation in clinical HCC.
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Neddylation impacts liver cancer metabolism in 
Phb1-KO mice
To further study neddylation impact on liver 
cancer, we used Phb1-KO mouse model. Prohibitin 1 is 
a highly conserved, ubiquitously expressed protein that 
participates in diverse processes including mitochondrial 
chaperone, growth and apoptosis. Liver-specific deletion 
of Phb1 in mice results in spontaneous liver injury, 
fibrosis, and HCC [18]. Like in clinical HCC, increased 
neddylation levels, measured as accumulation of Nedd8-
cullin conjugated levels, associated with the presence of 
malignant nodules in livers and hepatocytes from Phb1 
-KO mice were observed (Fig. 2A, Suppl. Fig. 1B). In 
agreement, neddylation was induced in human hepatoma 
cell lines compared to non-tumoral hepatocytes, (Suppl. 
Fig. 1C), and in other animal models that spontaneously 
develop HCC, such as the glycine N-methyltransferase 
(Gnmt)-KO mice [19] (Suppl. Fig. 1D). Considering the 
elevated neddylation levels in the Phb1-KO mice, the 
therapeutic potential of the small molecule neddylation 
inhibitor, MLN4924, was evaluated. For this purpose, 10 
Phb1-KO mice, from 5 to 6-months old, were selected and 
randomly assigned to two different experimental groups: 
(i) injected subcutaneously with MLN4924 (60 mg/kg 
body weight) and (ii) vehicle-treated, once a week for 8 
weeks. Importantly, longitudinal evaluation by in vivo 
high-frequency ultrasound fortnightly revealed a strong 
reduction in the liver tumor size in the MLN4924-treated 
mice (Fig. 2B, Suppl Table I) without visible biochemical 
side effects as a consequence of the MLN4924-treatment 
(Suppl. Fig. 2A, Suppl. Table II). Moreover, decreased 
tumor size in the MLN4924-treated group was associated 
with a down regulation of global neddylation, observed 
Figure 1: Global neddylation in HCC. (A) Nedd8 and NAE1 IHC analysis in human samples from normal liver (NL) (n=10) and 
hepatocarcinoma (HCC) (n=22) patients. (B) Box plots of Nedd8 and NAE1 gene levels in NL (n=200) and HCC (n=225) human samples 
from ONCOMINE database. (C) Nedd8 and NAE1 IHC and (D) mRNA expression analysis in good (n=16) and bad (n=13) prognosis 
HCC human samples. (E) Kaplan-Meier plot of overall survival of HCC patients grouped according to low or high Nedd8 expression. (F) 
Logistic regression to quantify the predictability of a Nedd8 model in better and poorer prognosis of HCC. Values are represented as mean 
± SEM. *p<0.05, **p<0.01 (HCC vs NL; Bad vs good prognosis).
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by decreased Nedd8-cullin conjugates and, of the already 
known Nedd8 target, HuR [8] (Fig. 2C-D). As expected, 
neddylation inhibition with MLN4924 promoted an 
upregulation of the cullin-targets c-Jun and Nrf2 (Suppl. 
Fig. 2B), as detected by Western blot analysis. In addition, 
neddylation inhibition in Phb1-KO mice reduced liver 
fibrosis (Suppl. Fig. 2A), further supporting the beneficial 
role of MLN4924-treatment without the appearance of 
secondary complications. High-throughput metabolomic 
analysis on liver samples was performed to highlight 
some of the mechanisms underlying tumor regression as a 
consequence of neddylation inhibition.
Wide targeted metabolomics data revealed a strong 
reduction of sphigomyelins (SM), SM(d18:0/22:0) (90%, 
p<0.05) together with decreased diacylglycerols (DAG) 
levels [DAG(32:1), DAG(32:2), DAG(34:2)] (~30% 
p<0.05) in MLN4924-treated Phb1-KO mice (Suppl. Table 
III, and Suppl Fig. 2C). On other hand, triacylglycerols 
(TAG) were found to be increased as a result of neddylation 
inhibition [TAG(54:6), TAG(54:7), TAG(56:7), 
TAG(56:8), TAG(58:10), TAG(58:9)]. Importantly, 
MLN4924 treatment increased the hepatic levels of 
some types of phosphatidylcholines (PC) [PC(18:0/20:4) 
(69% p< 0.05), PC(18:0/22:6) (89% p<0.05)] and 
reduced those of the phosphatidylethanolamines (PE) 
[PE(16:0/18:1) (54% p<0.05)] contributing to a significant 
shift (40%, p<0.05) in the 16:0/18:1 and 18:0/20:4 
species PC/PE ratio (Suppl. Table III). In the liver, PC 
can be formed either by the Kennedy pathway or by the 
phosphatidylethanolamine N-methyltransferases (PEMT) 
pathway. Phosphatidylcholines formed via PEMT pathway 
are primarily enriched in long-chain polyunsaturated fatty 
acids (PUFA), such as docosahexaenoic acid (22:6n-3) 
[20]. Thus, an increase in the PC(22:6n-3)/total PC ratio 
(20%, p<0.05) was identified in MLN4924-treated Phb1-
KO mice suggesting increased PEMT flux.
Moreover, we observed that the central carbon 
metabolism was tightly controlled by neddylation 
inhibition in Phb1-KO mouse (Suppl. Table IV, Suppl. Fig. 
2D). Importantly, pivotal metabolites like succinate [21, 
22] were reduced after MLN4924-treatment. In agreement, 
GTP levels, a readout metabolite from the catabolism of 
succinate mediated by succinyl-CoA synthetase, were 
diminished under these conditions. In addition, the hepatic 
content of malonyl-CoA, a classical β-oxidation inhibitor, 
was also downregulated in mice upon MLN4924 treatment 
(Suppl. Table IV, Suppl. Fig. 1D). Importantly, glycine, 
a metabolite that reflects proliferation rate across cancer 
cells [23], was attenuated (21%, p< 0.05) after NAE1 
inhibition. Finally, glycolic acid, the classical inhibitor 
of the aerobic glycolysis through lactate dehydrogenase 
(LDH) activity [24], was increased in the liver of 
Figure 2: In vivo neddylation inhibition blocks tumor progression. (A) Representative Western blot analysis of global 
neddylation (shown as neddylated cullins) in whole extracts from WT and Phb1-KO livers and isolated hepatocytes. (B) Reduction of 
tumor size in Phb1-KO mice after MLN4924 treatment determined by caliper measurement of the longest diameter in the transverse view 
of the liver. (C) Staining of liver sections from Phb1-KO MLN4924 treated and Phb1-KO untreated mice with Nedd8 and HuR antibodies. 
Graphical representations are shown on the right of each panel. (D) Western blot analysis of Nedd8 and HuR on liver lysates from Phb1-KO 
MLN4924 and Phb1-KO untreated animals. (Values are mean ± SEM. *p<0.05; Phb1-KO MLN4924 vs Phb1-KO).
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MLN4924-treated Phb1-KO mice. 
Overall, our data underscore that neddylation 
inhibition as a result of MLN4924 treatment to Phb1-KO 
mice is associated with tumor regression associated with 
metabolic reprogramming. 
Neddylation inhibition promotes apoptosis in 
Phb1-KO hepatocytes associated with a metabolic 
shift from oxidative phosphorylation to glycolysis
To further investigate the role of neddylation 
loss on tumor cell metabolism, we examined energetic 
metabolism using a Seahorse® XF24 Analyzer equipment 
in hepatocytes isolated from Phb1-KO mice. For this 
purpose, hepatocytes were harvested from 8-month 
old animals in order to obtain well-differentiated 
hepatocytes showing a protumoral phenotype. The cells 
upon neddylation inhibition, both with MLN4924 and 
Nedd8 silencing, displayed a reduction in the oxygen 
consumption rate (OCR), a surrogate of oxidative 
phosphorylation (OXPHOS) (Fig. 3A). Moreover, the 
extracellular acidification rate (ECAR), a measure of 
glycolysis, was increased as a result of neddylation 
reduction (Fig. 3B). The observed OXPHOS reduction 
and ECAR induction resultant of neddylation inhibition 
Figure 3: Oxidative Phosphorylation and Glycolysis are dependent on neddylation activity. (A) Oxygen consumption 
rate (OCR) and (B) extracellular acidification rate (ECAR) values in Phb1-KO hepatocytes 48 hours after MLN4924 treatment or Nedd8 
silencing.  The energetic response in cells was measured in the presence of oligomycin, FCCP and rotenone. (C) Caspase-3 activity in WT 
and Phb1-KO hepatocytes after 48 hours of MLN4924 treatment. (D) ATP levels and (E) ROS production in Phb1-KO hepatocytes after 
48 hours of MLN4924 treatment. (F) Phosphatidylethanolamine methyltransferase (PEMT) flux in Phb1-KO hepatocytes 48 hours after 
MLN4924 treatment or Nedd8 silencing. Values are represented as mean ± SEM. n=4 samples/time point. *p<0.05, **p<0.01, ***p<0.001 
(MLN4924 or siNedd8 vs control).
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were associated with an apoptotic response as analyzed 
by caspase-3 activity (Fig 3C). Importantly, apoptosis 
induction by MLN4924 treatment was only observed in 
Phb1-KO hepatocytes and not in healthy hepatocytes 
from wild type animals. Moreover, MLN4924 induced 
cell death in Phb1-KO hepatocytes was associated with 
a reduction in ATP (Fig. 3D) and augmented redox levels 
(Fig. 3E). 
Noteworthy, neddylation inhibition, using either 
MLN4924 or Nedd8 siRNA, led to a strong stimulation 
in the PEMT flux as shown for the incorporation of [3H] 
ethanolamine into PE and PC in Phb1-KO hepatocytes 
(Fig. 3F). The observed PEMT pathway induction as 
a consequence of neddylation inhibition was observed 
both following in vivo treatment as well as in isolated 
hepatocytes. Previous work has shown that MLN4924 
treatment induces apoptosis in hepatoma cells [25]. 
Here, we have extended this analysis and we have shown 
also that apoptosis mediated by neddylation inhibition 
induced either by MLN4924 or by Nedd8 silencing, in 
human hepatoma cells, is accompanied by a decrease in 
OXPHOS, an increase in the glycolytic flux and a higher 
activity of the PEMT pathway (Suppl. Fig 3A-E). 
All together our data support that neddylation 
inhibition-induced apoptosis in Phb1-KO hepatocytes 
is accompanied by alterations in cell metabolism as 
decreased OXPHOS, increased glycolytic flux and higher 
activity of the PEMT pathway. 
New neddylation targets identified in liver cancer
Many of the oncogenic drivers observed in cancer 
alter tumor-metabolism as part of their mode of action. 
LKB1 and Akt are well known metabolism regulators 
in healthy liver. However, the activity of both kinases 
has been associated with HCC development [11-14]. 
Importantly, IHC and Western blot analysis showed that 
LKB1 and Akt levels were considerably overexpressed in 
HCC patients, being further increased in those with poor 
outcome prognosis (Fig. 4A). Whereas increased protein 
levels of LKB1 are associated with the transcriptional 
upregulation of STK11 (the gene encoding for LKB1), the 
same is not valid for Akt (Fig. 4B). 
Notably, the logistic regression model showed a 
good predictability for the levels of LKB1, Akt and global 
neddylation (Fig. 4C) suggesting that the increased levels 
of LKB1 and Akt in patients with liver cancer is associated 
to elevated hepatic neddylation. In addition, LKB1 and 
Akt ROC curves provide a significant value of area under 
Figure 4: Association between LKB1, Akt and neddylation in human HCC. (A) LKB1 and Akt IHC analysis in human 
samples from normal liver (NL) and HCC human samples from patients with good and bad prognosis. Graphical representations are shown 
on the right of each panel. (B) LKB1 and Akt mRNA expression in human samples from patients with HCC with good or bad prognosis. 
(C) Pearson´s correlation between neddylation and LKB1 or Akt levels respectively. (D) ROC curves of LKB1 and Akt in good and bad 
prognosis of human HCC samples. The area under the ROC curve (AUC) measures the statistical potential of Akt and LKB1 to differentiate 
the two prognosis groups. Values are represented as mean ± SEM. *p<0.05 (Bad vs good prognosis).
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the curve (AUC) close to 1, indicating the good overall 
ability of the test to discriminate between good and bad 
prognosis (Fig. 4D). 
As observed in clinical HCC, LKB1 and Akt levels 
were also significantly overexpressed in the liver and 
hepatocytes from Phb1-KO mice (Fig 5A), although these 
proteins transcriptional levels were not significantly altered 
(Suppl. Fig. 4A). Importantly, the neddylation inhibition 
as a result of MLN4924-treatment was correlated with a 
reduction of the LKB1 and Akt oncogenic proteins (Fig. 
5B-C) only at the protein level (Suppl. Fig. 4B). LKB1 
is an upstream regulator of AMPK. However, treatment 
with MLN4924 was not associated with decreased AMPK 
activation (Suppl. Fig. 2E), suggesting an uncoupling 
between LKB1 and AMPK under neddylation inhibition in 
liver tumor models. Increased phosphorylation of AMPK 
under neddylation inhibition correlated with increased 
caspase-3 as observed earlier [11].
Furthermore, we evaluated the effect of the in vivo 
Nedd8 silencing, using siRNA approaches, in the well-
established in vivo tumorigenesis HepG2 xenograft mouse 
model. In these animals, a 66±11% decrease (p<0.05) in 
tumor size (Fig. 5D) and a reduction of the levels of HuR 
observed as a consequence of neddylation inhibition, were 
Figure 5: LKB1 and Akt levels are dependent of neddylation in HCC mice models. (A) Representative Western blot analysis 
of LKB1 and Akt in whole extracts from WT and Phb1-KO livers and isolated hepatocytes. (B) Staining of liver sections from Phb1-
KO MLN4924 treated and Phb1-KO untreated mice with LKB1 and Akt antibodies. Graphical representations are shown on the right 
of each panel. (C) Western blot analysis of LKB1 and Akt on liver lysates from Phb1-KO MLN4924 and Phb1-KO untreated animals. 
(D) Graphical representation of changes in tumor size in HepG2-xenografted nude mice. (E) Staining and graphical representation of 
quantitative analysis of each staining in HepG2-xenografted nude mice tumors. Values are represented as mean ± SEM. *p<0.05, **p<0.01 
(Phb1-KO MLN4924 vs Phb1-KO; siNedd8 vs siControl).
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also associated with decreased LKB1 and Akt levels (Fig. 
5E). As detected in vivo, neddylation inhibition, both after 
MLN4924-treatment and knockdown of Nedd8 by siRNA 
in Phb1-KO isolated hepatocytes was also accompanied 
with a fall in the total amount of the oncogenic proteins, 
LKB1 and Akt (Fig. 6A-B), without regulation at the 
transcriptional level (Suppl. Fig. 4C). In addition, Nedd8 
specific-protease cysteine (NEDP1) overexpression, which 
specifically removes Nedd8 molecules from conjugated 
substrates [26], also reduced LKB1 and Akt levels in 
Phb1-KO hepatocytes (Fig. 6C), without affecting their 
transcriptional regulatioh (Suppl. Fig. 4C). As expected, 
Nedd8-silencing accounts for decreased stability of 
LKB1 and Akt, as observed from the reduced half-life 
of these proteins after the inhibition of protein synthesis 
by cycloheximide (Fig. 6D). The correlation found 
between global neddylation and LKB1 and Akt levels, 
prompted us to hypothesize that LKB1 and Akt could be 
in partly regulated through neddylation. To verify this, 
we overexpressed His
6
-Nedd8 in hepatocytes from wild 
type animals. The enrichment analysis of His
6
-Nedd8 
conjugated proteins revealed enhanced molecular bands 
of LKB1 and Akt (Fig. 6E). 
In summary, we reveal for the first time that 
LKB1 and Akt are direct neddylation targets. As such, 
neddylation inhibition is able to impair LKB1 and Akt 
stabilization contributing to regulate the levels of these 
two oncokinases.
Figure 6: LKB1 and Akt as new targets of neddylation. (A) Representative Western blot analysis of total lysates from WT 
and Phb1-KO hepatocytes treated with MLN4924 for 48 hours using Nedd8, LKB1 and Akt antibodies. LKB1 and Akt levels were also 
evaluated by Western blot in Phb1-KO hepatocytes after (B) Nedd8 silencing and (C) NEDP1-V5 overexpression. (D) The stability of 
LKB1 and Akt proteins as the percentage of protein level remaining after treated with cycloheximide (CHX). Vertical bars are indicative of 
the calculated half-life for every protein. (E) FLAG and HA immunoreactive proteins in WT hepatocytes expressing FLAG-LKB1 or HA-
Akt and His
6
-Nedd8. Hepatocytes were cotransfected with FLAG-LKB1/HA-Akt and His
6
-Nedd8 plasmids, and FLAG/HA-containing 
proteins were purified using Ni2+-NTA and detected by Western blotting.
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LKB1 and Akt stabilization drives the metabolic 
reprogramming induced by neddylation inhibition
To investigate whether the neddylation inhibition 
induced-apoptosis in Phb1-KO isolated hepatocytes was 
partially mediated by the decrease in LKB1 and Akt 
protein stabilization, we overexpressed these two kinases 
under MLN4924 treatment (Fig. 7A). Overexpression 
of both LKB1 and Akt per se accounts for increased 
OCR and ECAR thereby promoting a more proliferative 
phenotype in these premalignant hepatocytes (Fig 7B-C). 
On the other hand, LKB1 and Akt silencing (Suppl. Fig. 
4D) was associated with decreased OCR and ECAR (Fig. 
7B-C). Moreover, MLN4924 treatment under LKB1 and 
Akt-overexpression did not significantly alter OCR and 
Figure 7: LKB1 and Akt stabilization play an important role on neddylation-induced metabolic disruptions in liver 
cancer. (A) Western blot analysis against Nedd8, LKB1 and Akt in Phb1-KO hepatocytes overexpressing Akt and LKB1 after 48 hours 
of MLN4924 treatment. (B) Basal oxygen consumption rate (OCR) and (C) extracellular acidification rate (ECAR) values in Phb1-KO 
hepatocytes after LKB1 and Akt overexpression and silencing. (D) OCR and ECAR were measured in Phb1-KO hepatocytes overexpressing 
LKB1 and Akt after 48 hours of MLN4924 treatment. The energetic response in cells was measured in the presence of oligomycin, FCCP 
and rotenone. (E) Caspase-3 activity in Phb1-KO hepatocytes overexpressing LKB1 and Akt after 48 hours of MLN4924 treatment. Values 
are mean ± SEM. *p<0.5, ***p<0.001 (LKB1/Akt overexpression and silencing vs control).
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ECAR levels (Fig 7D). Interestingly, boosting the levels 
of both LKB1 and Akt was sufficient to counteract the 
apoptotic response mediated by neddylation inhibition 
(Fig 7E). 
In summary, the restoration of LKB1 and Akt 
expression was able to block the metabolic reprogramming 
and associated cell apoptosis induced by neddylation 
inhibition. These data further support that both LKB1 and 
Akt destabilization partially drive the metabolic phenotype 
induced by lack of neddylation. 
DISCUSSION
Multiple signaling pathways appear to converge 
in HCC [1]. The current view of cancer progression 
highlights that cancer cells must undergo through a 
PTM regulation and metabolic reprogramming in order 
to progress in an unfriendly environment. Under this 
basis, the neddylation pathway is essential for cancer 
development through the activation of Cullin ring-ligases 
and the degradation of their substrates [4]. In addition, the 
neddylation-induced stabilization of other target proteins 
can occur. Herein, we have investigated the importance 
of neddylation in liver cancer signaling and metabolism 
and more importantly its potential as a new therapeutical 
approach. 
We provide strong evidences that high neddylation 
is associated with clinical HCC and poorest prognosis, 
suggesting that it provides an advantage to tumor cells. 
Moreover, in Phb1-KO HCC mice, reduced neddylation 
levels as a result of its pharmacological inhibition using 
the small molecule inhibitor MLN4924 was associated 
with a distinguishable metabolic fingerprint associated 
with tumor regression and characterized by: a) reduced 
levels of total SM and variety of DAG, succinate, GTP, 
malonyl-CoA, glycine; and b) augmented glycolic acid, 
TAG levels and PEMT flux. 
Recently, SM has emerged as an important molecule 
to generate bioactive sphingolipids through ceramides. 
SM synthase is an enzyme that generates SM and DAG 
from PC and ceramides. As such, reduced SM and DAG 
levels could reflect decreased SM synthase activity, 
which is inhibited when the hepatocytes enter into the 
S-phase after partial hepatectomy [27]. Based on these 
evidences our results clearly suggest an association 
between SM synthase, with reduced SM and DAG levels 
and diminished proliferative phenotype. Moreover, DAG 
cellular content has been previously associated with 
oxidative stress, redox misbalance and mitochondrial 
dysfunction [28]. Also, DAG exhibits a dual role in 
cell biology serving as substrate for cell membrane 
biosynthesis (phospholipids) and energy storage as TAG. 
Thereby, under neddylation inhibition conditions, reduced 
DAG levels as a result of improved mitochondrial function 
and decreased proliferation may be channeled to TAG 
synthesis. Lipidomics and enzymatic analysis showed 
that neddylation inhibition resulted in augmented PEMT 
activity in Phb1-KO mice. These data are in agreement 
with the potential role of PEMT as a liver-specific tumor 
suppressor and the inhibitory effects exerted by the 
PEMT-dependent PC species in the Kennedy pathway 
required for hepatocyte proliferation [29, 30]. Targeted 
metabolomics performed in regressive liver tumors of 
Phb1-KO mice after neddylation inhibition revealed an 
improvement in TCA cycle and mitochondrial functions 
as shown by a reduction in succinate, GTP and glycine 
levels, metabolites often described as pro-proliferative 
and showing hepatic damage-inducing properties [21-
23]. Moreover, reduced malonyl-CoA levels account 
for augmented β-oxidation and formation of acetyl-CoA 
to enter and further sustain restored TCA cycle flux. As 
a result of improved mitochondrial function, aerobic 
glycolysis is reduced as shown by augmented glycolic acid 
levels, an inhibitor of lactate dehydrogenase activity [24]. 
In summary, following neddylation inhibition in Phb1-
KO mice, a reduced malignant phenotype translating into 
tumor regression as a consequence of tumor cell death is 
observed. 
In the last couple of years, neddylation inhibition 
has been widely implicated in tumor cell death in 
several tissues [16]. In order to further study neddylation 
inhibition-induced tumor cell death, we used well-
differentiated tumor Phb1-KO hepatocytes. Herein, 
the metabolic slowdown observed after neddylation 
inhibition was due to the negative impact that the absence 
of Nedd8 has in the OXPHOS pathway ending in cancer 
cell apoptosis. The mitochondrial apoptosis induced by 
neddylation inhibition was also associated with an increase 
of the PEMT flux as previously observed [31]. These 
results are in agreement with early evidences implicating 
MLN4924 and thereby neddylation inhibition actions 
on cellular redox dysfunction [32]. As a consequence 
of decreased OXPHOS, tumor cells need to look for 
alternative energetic pathways such as glycolysis thereby 
resulting in increased glycolytic flux. Interestingly, the 
metabolic switch from OXPHOS to glycolytic flux, 
usually advantageous to tumor cells, in here is associated 
with increased tumor cell apoptosis. We speculate that 
this is due to the fact that under neddylation inhibition the 
cellular energetic pool, already compromised by reduced 
OXPHOS, is being channeled to the high-demanding 
energetic process of DNA rereplication, previously shown 
to be induced in neddylation inhibition [33]. Importantly, 
a reduction in the OXPHOS/glycolysis metabolic ratio as 
a consequence of neddylation inhibition is associated with 
augmented tumor cell apoptosis. 
Considering that LKB1 and Akt kinases play 
an important role in energetic metabolism regulation 
and have been previously shown to be targets of PTM 
regulatory events, we hypothesized that LKB1 and Akt 
are potential neddylation targets. In agreement, during 
the transformation of primary hepatocytes, in the liver of 
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Phb1-KO HCC mice and more importantly in a cohort of 
human HCC samples, a strong correlation in the levels 
of LKB1, Akt and Nedd8 in the liver was observed. In 
here, we report for the first time that both LKB1 and Akt 
are new targets of neddylation modifications. Indeed the 
overexpression of either LKB1 or Akt kinases counteracts 
the metabolic reprogramming response mediated by 
neddylation inhibition associated to mitochondrial 
apoptosis (Suppl. Fig. 5). This is in agreement with early 
reports showing that LKB1 deficient cells are less able to 
restore ATP levels in response to metabolic stress and thus, 
more susceptible to cell death [34], and with the important 
role of Akt in OXPHOS and glycolysis balance [35]. 
Summing up, our results reveal for the first time 
a completely new and unexplored role of neddylation in 
the stabilization of the key oncogenic hallmarks, LKB1 
and Akt. Moreover, we provide evidences that LKB1 and 
Akt stabilization plays an important role on neddylation-
induced metabolic disruptions in liver cancer further 
suggesting neddylation as a potential therapeutic target in 
HCC. 
MATERIALS AND METHODS
Human Samples
Surgically resected liver specimens of 22 patients 
with HCC (10 Hepatitis C, 10 ASH and 2 NASH) 
were examined. The Basque Research Biobank (http://
www.biobasque.org) provided the data and type of 
biospecimen. For the bad and better prognosis analyses 
we used samples from 47 patients with liver cirrhosis and 
HCC detected during surveillance. They had preserved 
liver function and corresponded to BCLC stage A (n=34) 
and B (n=13). These patients are part of another study, 
reported elsewhere (Gut, submitted). All tissues samples 
from this study were from US-guided liver biopsy of HCC 
lesions. In brief, compensated patients with liver cirrhosis 
under ultrasonographic surveillance for HCC, when first 
identified as having developed a HCC lesion underwent 
a dedicated imaging protocol (2 computed tomography 
exams 6-weeks apart in a absence of any other therapy 
to evaluate growth speed) and an US-guided liver biopsy 
(to define transcriptomic characteristics of tumor). After 
the 2nd computed scan, patients underwent therapy 
according to internationally accepted guidelines. Patients 
were divided in 4 quartiles according to HCC volume 
doubling time and survival evaluated according to these 
quartiles. Patients of the first quartile (Doubling time< 53 
days) had a definitively worse prognosis that those of the 
other quartiles (median survival 11 months vs 41, 42 and 
47 months, respectively). Healthy human liver was used 
as control for immunostaining. Patients gave informed 
consent to all clinical investigations, in according to the 
principles embodied in the Declaration of Helsinki. 
Animals
Three to eight month-old male Phb1-KO mice [18], 
breded in the animal facility at the CIC bioGUNE, were 
used. Animal procedures were approved following the 
CIC bioGUNE Animal Facility’s guidelines with AALAC 
certificate.
Cell Lines
In vitro experiments were performed using primary 
mouse hepatocytes from Phb1-KO and the human 
hepatoma cell lines BCLC3 and BCLC5, characterized 
and provided by Dr. Bruix and Dr. Boix (BCLC group. 
Hospital Clinic, Barcelona, Spain). 
Isolation and Culture of Primary Hepatocytes
Primary hepatocytes were isolated from male 
C57BL6 WT and Phb1-KO mice via collagenase perfusion 
as described before [8].
Cell Treatment with MLN4924
MLN4924 was provided by Millenium 
Pahrmaceuticals Inc. Phb1-KO hepatocytes were treated 
with MLN4924 at the dose of 3 µM for 48 hours using 
DMSO as control. 
Cell Transfection
Phb1-KO hepatocytes were transfected with 2 µg 
of pcDNA3-FLAG-LKB1 (Addgene), pLNCX1-HA-
Akt (kindly provided by Dr. Carracedo, CIC bioGUNE, 
Spain) or cysteine protease (NEDP1-V5) plasmids using 
jetPRIMETM reagent (Polyplus). Two µg of pcDNA3-
LacZ (Invitrogen) and pLNCX1 plasmids (provided by 
Dr. Carracedo) were used as negative controls of LKB1 
and Akt, respectively. 
In vitro Silencing
Primary Phb1-KO hepatocytes were transfected 
with 100 nM Nedd8, LKB1 and Akt siRNA (Qiagen) using 
jetPRIMETM reagent (Polyplus). Controls were transfected 
with an unrelated siRNA (Qiagen). Protein knockdown 
was confirmed by Western blotting. siRNA sequences are 
shown in Supplementary Table V.
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In vivo MLN4924 Treatment
MLN4924 was injected subcutaneously into 
10 Phb1-KO mice, once a week at a dose of 60 mg/kg 
for 8 weeks, following the Millennium Corporation 
communication. Age-matched Phb1-KO controls, 
corresponding to the untreated group, were injected with 
the respective vehicle at the same time intervals.
In vivo Nedd8 silencing
5x106 HepG2 cells were injected into 10 
male athymic C57BL/6J nude mice, as described in 
Supplemental Material. One week after cell inoculation, 
animals were divided into 2 experimental groups: (i) 
siControl (n=5) and (ii) siNedd8 (n=5), 50 µM-siRNA 
dose were intraperitoneally injected thrice a week using 
jetPEITM reagent (Polyplus), following manufacturer’s 
instructions. 
Immunohistochemistry
Paraffin embedded liver samples were sectioned, 
dewaxed and hydrated. All procedures were done 
according to standard protocols with EnVision+ System 
HRP (Dako). Finally, samples were incubated with Vector 
Vip substrate (Vector) for purple color development. 
10 random images per sample were taken with a 10x 
objective from a microscope AXIO Imager D1 (Carl Zeiss 
AG, Oberkochen, Germany). Quantification of staining 
intensity or area of each sample were calculated using the 
manual selection tool of FRIDA software (FRamework for 
Image Dataset Analysis) http://bui3.win.ad.jhu.edu/frida/. 
Stained area was measured using ImageJ64 software 
(NIH), images were transformed to RGB stacks, manually 
thresholded for selection of the stained área and measured 
with the measure tool to calculate the area percentage. 
A description of the antibodies used is provided in 
Supplementary Table VI.
Protein Isolation & Western Blotting
Extraction of total protein from cultured cells 
and livers was performed as described [8]. 4 to 25µg of 
protein were electrophoresed on sodium dodecyl sulfate-
polyacrylamide gels and transferred onto membranes. 
A description of the antibodies used is provided in 
Supplementary Table VI. Band intensities were quantified 
using the ImageJ software and normalized to the β-Actin 
housekeeping. All experiments were performed at least 5 
times.
RNA Isolation and Quantitative Real-Time PCR
RNA was isolated with Trizol (Invitrogen), and 
its concentration and integrity were determined. PCRs 
were performed using iQ™ SYBR® Green Supermix 
(Biorad) and the Bio-Rad iCycler thermocycler (Bio- 
Rad, Hercules, CA). The Ct values were extrapolated to a 
standard curve, and data was then normalized to the house-
keeping expression (18S and GAPDH). The sequences of 
primers used are described in Supplementary Table VII.
Apoptosis Measurement
Caspase-3 activity was measured as previously 
described [8].
ATP Levels
ATP levels were measured by using the commercial 
available kit ATPliteTM (Perkin Elmer).
Evaluation of ROS production 
ROS production was measured by flow cytometry 
analysis using CellROXTM Deep Red according to 
manufacters intructions (Life Technologies). 
Cycloheximide Treatment
Phb1-KO hepatocytes were transfected with Control 
or Nedd8 siRNA as described. Later, cycloheximide 
(CHX; 50 µg/mL) was added, and, at the indicated times, 
cells were lysed. Protein was analyzed by Western blotting 
using the indicated antibodies, quantified with Image J 
software, and presented as the percentage of remaining 
protein. Data are representative from three independent 
experiments. 
Protein-Histidine Affinity Purification Using 
Nickel-Nitrilotriacetic Acid Beads
Phb1-KO hepatocytes were cotransfected with 2µg 
of His
6
-Nedd8 and FLAG-LKB1 or HA-Akt constructs 
using jetPRIMETM reagent (Polyplus). Cells were lysed in 
6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M 
Tris-HCl pH 8, plus 10 mM β-mercaptoethanol and 5mM 
Imidazole. Lysates were mixed with 70 µl of low density 
Ni2+-NTA-agarose beads (ABT) precoated with BSA 
and prewashed with lysis buffer. Lysates were incubated 
with the beads for 3 hours at RT, successively washed 
first with lysis buffer, then twice with 8 M urea, 0.1 M 
Na
2
HPO
4
/NaH
2
PO
4
, 0.01 M Tris-HCl pH 8 plus 10 mM 
β-mercaptoethanol, and finally thrice with 8 M urea, 0.1 M 
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2
HPO
4
/NaH2PO4, 0.01 M Tris-HCl pH 6.3 plus 10 mM 
β-mercaptoethanol. After last wash, the beads were eluted 
with 200 mM Imidazole in 5% SDS, 0.15 M Tris-HCl pH 
6.7, 30% glycerol, 0.72 M β-mercaptoethanol. The eluates 
were subjected to SDS-PAGE and the proteins transferred 
to a nitrocellulose membrane for Western blotting against 
FLAG (Sigma) and HA (Covance) antibodies.
In vivo Ultrasound Imaging
The Vevo 770 high-frequency Ultrasound (US) 
system (VisualSonics Inc., Toronto, Ontario, Canada) was 
used employing a 40-MHz probe (Scanhead RMV-704, 
VisualSonics Inc., Toronto, Ontario, Canada). Further 
information is provided in Supplementary Material. 
Measurements of oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) 
A Seahorse Bioscience XF24-3 Extracellular Flux 
Analyzer was used to measure the rate change of dissolved 
O2 and pH in medium immediately surrounding adherent 
cells. Further information is provided in Supplementary 
Material. 
Quantification of Phosphatidylethanolamine 
and Phosphatidylcholine Synthesis Rates using 
Radioisotopes
Hepatocytes were incubated with [3H]ethanolamine 
(5 µCi/ml). Cells and medium were separated, lipids 
extracted, separated, and the label incorporated into 
phosphatidylethanolamine (PE) and phosphatidylcholine 
(PC) determined in a scintillation counter.
Metabolomics Analysis
UPLC®-MS metabolomics analysis was performed 
in livers from untreated Phb1-KO and MLN4924 treated 
mice. The specific procedures, such as metabolite 
extraction, data processing, normalization and statistical 
analysis have been previously detailed and are described 
extensively in Supplementary Material. 
Statistical Analysis
All experiments were performed at least in triplicate. 
Data are expressed as mean ± SEM. Statistical significance 
was estimated with Student´s t test. A p value < 0.05 was 
considered significant.
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